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1330 The Journal of Thoracic and CardObjective: Prosthetic and bioprosthetic materials currently in use lack growth potential
and therefore must be repeatedly replaced in pediatric patients as they grow. Tissue
engineering is a new discipline that offers the potential for creating replacement
structures from autologous cells and biodegradable polymer scaffolds. In May 2000, we
initiated clinical application of tissue-engineered vascular grafts seeded with cultured
cells. However, cell culturing is time-consuming, and xenoserum must be used. To
overcome these disadvantages, we began to use bone marrow cells, readily available on
the day of surgery, as a cell source. The aim of the study was to assess the safety and
feasibility of this technique for creating vascular tissue under low-pressure systems such
as pulmonary artery or venous pressure.
Methods: Since September 2001, tissue-engineered grafts seeded with autolo-
gous bone marrow cells have been implanted in 42 patients. The patients or their
parents were fully informed and had given consent to the procedure. A 5-mL/kg
specimen of bone marrow was aspirated with the patient under general anes-
thesia before the skin incision. The polymer tube serving as a scaffold for the
cells was composed of a copolymer of L-lactide and -caprolactone (50:50). This
copolymer is degraded by hydrolysis. The matrix is more than 80% porous, and
the diameter of each pore is 20 to 100 m. Polyglycolic acid woven fabric with
a thickness of 0.5 mm was used for reinforcement. Twenty-three tissue-
engineered conduits (grafts for extracardiac total cavopulmonary connection)
and 19 tissue-engineered patches were used for the repair of congenital heart
defects. The patients’ ages ranged from 1 to 24 years (median 5.5 years). All
patients underwent a catheterization study, computed tomographic scan, or both,
for evaluation after the operation. The patients received anticoagulation therapy
for 3 to 6 months after surgery.
Results: Mean follow-up after surgery was 490  276 days (1.3-31.6 months,
median 16.7 months). There were no complications such as thrombosis, stenosis, or
obstruction of the tissue-engineered autografts. One late death at 3 months after total
cavopulmonary connection was noted in patient with hypoplastic left heart syn-
drome; this was unrelated to the tissue-engineered graft function. There was no
evidence of aneurysm formation or calcification on cineangiography or computed
tomography. All tube grafts were patent, and the diameter of the tube graft increased
with time (110%  7 % of the implanted size).
Conclusion: Biodegradable conduits or patches seeded with autologous bone mar-
row cells showed normal function (good patency to a maximum follow-up of 32
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ratio and is degraded by hydrolysis after a few
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Tmonths). As living tissues, these vascular structures may have the potential for
growth, repair, and remodeling. The tissue-engineering approach may provide an
important alternative to the use of prosthetic materials in the field of pediatric
cardiovascular surgery. Longer follow-up is necessary to confirm the durability of
this approach.
CH
DVarious vascular grafts are commonly used in the re-construction of congenital heart defects in children.However, current prosthetic or bioprosthetic materials
lack growth potential, and subsequent replacements are there-
fore required in pediatric patients.1,2 Tissue engineering is a
new discipline that offers the potential to create replacement
structures from autologous cells and biodegradable polymer
scaffolds.3 Because tissue engineering constructs contain liv-
ing cells, they may have the potential to grow, self-repair, and
self-remodel. The application of this technique to cardiovas-
cular surgery was pioneered by Drs Mayer and Vacanti in
1993 at the Children’s Hospital, Boston.4
With the tissue-engineering technique, we demonstrated
the feasibility of tissue engineering heart valve leaflet and
pulmonary arterial graft in a large animal model in 1995 and
1997, respectively.5-9 After the successful results of the
supplementary examination in a dog inferior vena cava
replacement model, the institutional review board in Tokyo
Women’s Medical University approved the clinical trial of
these technique, with the patient’s parents’ thoroughly in-
formed consent.10,11 In May 2000, peripheral pulmonary
artery was successfully reconstructed in a 4-year-old girl
with the patient’s own venous cells.12 After that, 3 patients
underwent tissue-engineered graft implantation with cul-
tured autologous venous cells. On the basis of the large
animal experiments, we began to use bone marrow cells
(BMCs) from the anterior superior spine, readily available
on the day of surgery, as a cell source, because cell culturing
was time-consuming and xenoserum was required. Our ex-
perimental work showed evidence that BMCs contribute to
the construction of tissue-engineered vascular autografts in
vivo.13
Thus far, no clinical investigations have been reported.
The institutional review board approved human clinical
trials of this new technique. This study presents intermediate-
term clinical results of tissue-engineered vascular grafts
created by in vitro seeding of autologous bone marrow
mononuclear cells on biodegradable polymer scaffolds.
Material and Methods
Biodegradable Scaffolds
A copolymer of lactide acid and -caprolactone was synthesized
by ring-opening polymerization. This copolymer is a polyester
with a molar composition of lactide and -caprolactone at a 50:50months in vivo. The
he Journal of Thoracicmatrix is more than 80% porous, with a pore diameter of 20 to 100
m. A woven fabric (thickness 0.5 mm) made with poly-L-lactide
acid (PLLA, n 22) or polyglycolic acid (PGA, n 20) was used
for reinforcement of the porous matrix. The PGA fibers were
degraded by hydrolysis in approximately 2 months, and the PLLA
fibers were degraded in 2 years. With these polymers, we fabri-
cated a hybrid tubular scaffold that was 12 to 24 mm in diameter,
13 cm in length, and 0.6 to 0.7 mm in thickness. This fabrication
was achieved by pouring a solution of the copolymer of lactide
acid and -caprolactone onto the PLLA or PGA woven fabric
sheet, followed by freeze-drying under vacuum (Figure 1). The
tensile strength of the PLLA and PGA fiber in warm saline was
measured with an Instron tester (model 4302; Instron Corporation,
Figure 1. Macroscopic finding of biodegradable scaffolds and
scanning electromicroscopic findings of polymer scaffolds. Upper
left, Macroscopic finding; 18 mm in diameter.Copolymer of L-
lactide and -caprolactone synthesized by ring-opening polymer-
ization, with weight composition ratio of L-lactide and -capro-
lactone at 50:50. Polymeric woven scaffold composed of
polycaprolactum and polylactic acid reinforced with PGA mesh.
Bars represent 200 m (middle left), 100 m (lower left, upper
right), and 50 m (middle right, lower right).Canton, Mass) at various time points.
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Cell harvest. As described previously, there were several mod-
ifications to isolation of BMCs and seeding on the scaffold.
Briefly, recent methods are described here. With the patient under
general anesthesia, BMCs (approximately 4-5 mL/kg body weight)
were aspirated into a syringe containing heparin (100 units/mL
BMCs) from the anterior superior iliac spine of a patient with a
puncture needle. Aspirated BMCs were passed through a nylon
cell strainer (Becton Dickinson, Franklin Lakes, NJ) to remove fat
and bone fractions. BMCs were centrifuged with Histopaque-1077
(Sigma, St Louis, Mo) as described previously.11
Seeding onto the scaffold. After several washing and concen-
tration steps, obtained mononuclear BMCs were seeded onto the
biodegradable polymer by pipetting. The outer surface of the
seeded biodegradable scaffolds was then sprayed with fibrin glue
(Tisseel; Baxter, Vienna, Austria). The seeded biodegradable scaf-
fold was then kept in the patient’s own serum for approximately 2
to 4 hours at 37°C in 100% humidity and a 5% carbon dioxide
atmosphere until use. Approximately 300,000 cells/cm2 were used
for cell seeding.
Quality control of the tissue-engineered grafts. To verify that
seeded cells remained in the scaffold, the remnants of the graft
before implantation were taken as a sample and examined by
scanning micrography with Giemsa staining (Sigma) and immu-
nohistochemical methods. Anti-CD31–conjugated monoclonal an-
tibodies (Sigma) were used to identify the cell type. Cell counting
was performed by the method previously described by Otto.14
Patients
From May 2000 until March 2004, a total of 42 consecutive
patients received tissue-engineered vascular autografts seeded
with BMCs (Table E1). Informed consent was obtained directly
from patients older than 20 years and from the parents of
younger patients. Twenty-three patients had a tube graft as an
extracardiac total cavopulmonary connection (TCPC) graft. In
the other 19 patients, a sheet-type patch was used. The mean
age at operation was 7.3 years (range 1-24 years), and the mean
body weight was 21.7 kg (range 7.5-64 kg). Inclusion criteria
for patients for this procedure were as follows: elective surgery,
age younger than 30 years, patients or familial full understand-
ing of the procedure, and good quality of other organ function.
Eighteen patients were male, and 24 were female. Thirty-six
patients had undergone one or more previous operations, as
described in Table E1. To examine the inflammatory reaction
early after surgery, 20 patients who underwent TCPC at the
same times (mean age 6.3  3.1 years) with foreign materials
served as a control group. White blood cell counts and maxi-
mum postoperative C-reactive protein level were compared
between groups.
Follow-up
Follow-up visits of the patient were scheduled at 6 to 12 months
postoperatively and yearly thereafter. During follow-up visits,
transthoracic echocardiography and multislice computed to-
mography, cineangiography, or magnetic resonance imaging
angiogram were performed. Anticoagulation therapy with war-
farin sodium and aspirin was continued until 3 to 6 months after
the operation. International normalized ratio was kept within
1332 The Journal of Thoracic and Cardiovascular Surgery ● Jun1.5 to 2.0. Thereafter, anticoagulation therapy with aspirin
alone was continued for 12 months postoperatively.
Laboratory and Clinical Evaluation
The clinical evaluation was performed to detect whether there was
any evidence of immunologic or inflammatory activation, such as
leukocytosis or increasing C-reactive protein, during the first week
after surgery. At follow-up visits, additional clinical evaluations, such
as physical examination, chest roentgenography, and electrocardiog-
raphy, were performed.
Changes in Transectional Area of Extracardiac TCPC
Graft
At 1 year after implantation, computed tomography or magnetic
resonance imaging was performed. Because the transectional
shapes often appeared elliptic, the changes in maximal transec-
tional area were calculated and compared with the area of the
implanted tube. Calculation was performed according to the fol-
lowing formula: % Area change  [(Major axis  Major axis of
graft) (Implanted tube diameter)2]/(implanted tube diameter)2
100%. Seven of 23 patients who underwent TCPC were included
in this calculation.
Results
Biodegradable Scaffolds
The PGA fibers were degraded by hydrolysis in approxi-
mately 2 months, the PLLA fibers in 2 years. The remaining
tensile strengths of the PLLA fiber were 98.2% at 13 weeks,
88.1% at 26 weeks, 61.3% at 52 weeks, and 23.1% at 78
weeks; those of the PGA fiber were 81.3% at 1 week, 48.8%
at 2 weeks, 7.6% at 3 weeks, and 4.6% at 4 weeks.
Quality Control of the Tissue-Engineered Grafts
Mean cell number seeded onto the scaffold was 320,000 
29,900 cells/cm2. Scanning electromicrography showed the
presence of seeded cells attached to the polymer surface
(Figure E1). Giemsa staining showed a sufficient number of
seeded monolayer cells in the inner space of the scaffold
wall. Immunohistochemical staining for anti-CD34 and
fluorescence-activated cell sorter analysis demonstrated that
obtained mononuclear cells contained approximately 3%
anti-CD34–positive cells (Figure E2).
Follow-up
Follow-up was 100% complete. Mean follow-up was 16.3
months (range 1.3-31.6 months, median 16.7 months).
Mortality
There were no in-hospital deaths after surgery. One patient
with hypoplastic left heart syndrome died 3 months after the
TCPC operation because of progressive tricuspid regurgita-
tion and congestive heart failure. This late death was not
related to the implanted tissue-engineered graft.
e 2005
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During follow-up, there were no graft-specific lethal compli-
cation, such as rupture, thromboembolism, or aneurysm for-
mation. In 1 patient, the tissue-engineered graft was replaced
with a polytetrafluoroethylene patch 2 months after the original
surgery because of unexpected slower tissue growth on the
patch used for lateral tunnel procedure, which had caused
massive right-to-left shunting. This patient recovered quickly
after this surgical intervention and is currently in New York
Heart Association functional class I. The histologic findings of
the explanted patch are shown in Figure 2. The surface of the
patch was covered with endothelial-appearing monolayer cells.
In the medial layer, there were many collagen fibers and no
evidence of calcification.
Laboratory and Clinical Evaluation
Fever of unknown origin has not been seen in any of the
patients. Maximum elevated temperatures were in the
range of 37.4°C  0.8°C after surgery. Further temper-
ature measurements till discharge were performed with-
out any increase in temperature. Inflammatory reaction
early after operation is shown in Figure E3. There was no
statistically significant difference between the tissue-en-
gineering group and a control group randomly chosen for
the same period. Transthoracic echocardiography, multi-
slice computed tomography, or magnetic resonance im-
aging showed calcification to be absent in the tissue-
engineered grafts for all investigated patients. Pulmonary
angiography showed persistent patency in the peripheral
pulmonary artery that was reconstructed with a tissue-
engineered patch (Figure 3).
The Journal of ThoracicChanges in Area During Follow-up
As shown in Figures 4, 5, and E4, maximal transectional
area was calculated and compared with the implanted
size in the TCPC group. In patients with azygous con-
nection (in which only hepatic flow goes up through the
tissue-engineered graft), the larger grafts implanted tended
to decrease in diameter with time. Depending on the flow
amount, some grafts decreased in diameter and some in-
creased, which seemed to be some sort of environmental
adaptation of the tissue-engineered grafts (Figure 6).
Discussion
A good quality biologic material for use in pediatric heart
surgery is not yet available. Allogeneic tissue and prosthetic
materials degenerate rapidly relative to the course in older
patients.15,16 Furthermore, these materials are nonviable
structures, limiting longer term durability. Currently used
prosthetic or bioprosthetic materials, even allogeneic mate-
rials, lack growth potential and inevitably require reinter-
vention within 10 to 15 years after the definitive surgery in
pediatric patients.17 Especially in young patients, there is
increased calcium turnover, and antimineralization treatments
can only decrease this in part.18,19 A tissue-engineering ap-
proach with biodegradable materials and autologous cells
might overcome these deficits.
We have previously reported the usefulness in human
beings of a tissue-engineered autograft made with cultured
cells seeded onto a biodegradable polymer.12 This innova-
tive challenge was based scientifically on several animal
experiments.5-10 Although these procedures use harvested
Figure 2. Histopathologic findings on explanted patch
in patient with reoperation. Arrows indicate endothe-
lium-like cells. A, Hematoxylin-eosin stain, original
magnification 400; B, Masson stain, original magnifi-
cation 400; C, Victoria blue, original magnification
400; D, hematoxylin-eosin stain, original magnifica-
tion 800.vessel walls, the process of cell isolation introduces a risk of
and Cardiovascular Surgery ● Volume 129, Number 6 1333
Surgery for Congenital Heart Disease Shin’oka et al
CH
Dinfection and a potential inability to culture sufficient cells
for seeding onto the biodegradable polymer. Culturing cells
requires substantial time, which is not available in emer-
gency cases, and the use of serum from other species in the
culture medium reduces the merit of the procedure. The
benefits of using autologous cells for tissue engineering are
that the patients do not need a donor and that there is no fear
of rejection. When using BMCs, we were able to obtain
sufficient cells on the day of surgery. In consequence,
patients did not need extra hospitalization for vein harvest-
Figure 4. Magnetic resonance image 9 months after implantation
of TCPC graft (patient 8). White arrow indicates location of
tissue-engineered conduit.
1334 The Journal of Thoracic and Cardiovascular Surgery ● Juning. In fact, although some patients made a preliminary
hospital visit to harvest vein walls, sufficient cells were not
obtained by culturing. Furthermore, smaller quantities of
culture medium and other reagents are required, leading to
improved cost-effectiveness.
From 2001, we changed cell source in tissue engineering
for clinical applications because Noishiki and colleagues20
reported that BMCs implanted onto the surface of an arti-
ficial graft led to earlier endothelialization in a large animal
model, and it has been reported that some multipotential
cells in bone marrow have the potential to differentiate into
several cell types in vivo.21 Furthermore, previous studies
have shown the existence of endothelial progenitor cells
derived from bone marrow, which contribute to vasculogen-
esis and angiogenesis,22-24 and recent studies have demon-
strated that endothelial cell lineage cells have potential in
endothelialization.25-27 Recently, we proved the contribu-
tion of seeded and circulating BMCs in tissue engineering
vascular autografts in a dog model.13 On the basis of these
reports and our experimental results,9 we were certain that
seeding BMCs onto the polymer would result in a valuable
tool for constructing tissue-engineered materials.
After the initial three implantations of tissue-engineered
grafts seeded with venous cells, we retrospectively analyzed
these first implantation data and compared these with those
from the new technique. There were no difference in any
data at any point (unpublished data).
Anticoagulation therapies have been administered to
all patients, because animal experiments showed that it
usually took 2 weeks to accomplish the complete endo-
thelialization on the inner surface of the grafts. We
decided to use the anticoagulation therapy for 3 months
in clinical setting for the first clinical trials. International
normalized ratio was kept between 1.5 and 2.0. During
Figure 3. Pulmonary angio-
grams of patient 31. A, Lateral
view of pulmonary angiogram
before operation showed pe-
ripheral stenosis (white arrow-
head) with aneurysmal forma-
tion (white arrow) after balloon
angioplasty. B, Same view 6
months after operation. White
arrows indicate location of tis-
sue-engineered patch.the early postoperative period, heparin was continuously
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Dinjected, and anticoagulation time was controlled be-
tween 180 and 230 seconds. After discharge from the
hospital, we gave 5 mg/kg of aspirin and warfarin for 3
months to protect patients from thromboembolic compli-
cations. We assumed that autologous tissue would not
necessitate anticoagulation and that patients would be
free from medication from then on. The duration of
Figure 6. Percentage changes in cross-sectional area of tissue-
engineered grafts 1 year after operation.
The Journal of Thoracicwarfarin treatment could be shortened in the future; this
would improve quality of life, especially for young
women who want to become pregnant and need to be free
from anticoagulation therapy such as warfarin.
Regarding the differentiation of BMCs, this method has
potential risks, such as bone formation or neoplasm forma-
tion. In our 4-year experience, however, there was no cal-
cification or neoplasm formation in 42 patients.
This therapy is in its infancy, and it is true that several
problems remain to be resolved at this time. More ideal
biodegradable scaffolds, better procedures for cell prepara-
tion, and improved culture medium should be investigated
in the near future. We do hope that autologous tissue-
engineered materials will offer several advantages for chil-
dren around the world who require cardiac surgery.
Limitations of the Study
This study was not randomized trial or a controlled study. It
was also a small study, with a small number of patients. We
believe it to be the only safety and feasibility study of
tissue-engineered grafts in the clinical setting to date.
Conclusion
In conclusion, tissue-engineered vascular grafts were safe
and feasible in pediatric cardiovascular surgery and
Figure 5. Measurements of ma-
jor and minor axes of tissue-
engineered grafts in patients 2
(A), 4 (B), and 12 (C). Upper row,
Anteroposterior view; lower
row, lateral view.showed excellent hemodynamic performance during in-
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Dtermediate-term follow-up without anticoagulation ther-
apy. It appears that the application of biodegradable
scaffold with seeded BMCs might be able to decrease the
need for reintervention in growing pediatric patients.
Avoidance of anticoagulation therapy will probably im-
prove quality of life. Because our results in both the
clinical setting and the experimental model were quite
encouraging, we believe that the tissue-engineering ap-
proach may play an important role as an alternative
method to polytetrafluoroethylene grafts or allografts,
especially in the field of pediatric cardiovascular surgery.
The potential durability of these tissue-engineered con-
structs will be determined by longer follow-up.18,19
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Discussion
Dr John Mayer, Jr (Boston, Mass). First, I congratulate
Shin’oka and colleagues from the Tokyo Women’s Medical
University on their pioneering clinical efforts in applying a
tissue-engineering approach to the creation of devices for car-
diovascular application. It has been gratifying to me that Dr
Shin’oka’s work has progressed from the earliest successful
feasibility studies that he and Chris Breuer successfully com-
pleted in the laboratory several years ago and has now reached
the point of a clinical trial.
Dr Shin’oka’s use of autologous BMCs to seed biodegradable
graft materials has confirmed in human beings what Fraser Suth-
erland presented at this meeting last year in an ovine pulmonary
valved conduit model, that bone marrow mononuclear cells can be
a clinically applicable source of cells for tissue-engineered con-
structs in the cardiovascular system.
However, there are a number of unanswered questions for this
emerging field of cardiovascular tissue engineering, and I would
like to ask Dr Shin’oka a few questions on his experience thus far.
One fundamental question is what happens to the cells that are
seeded onto the scaffolds after the scaffolds are implanted? If I
understand the article correctly, there are at least 2 scaffolds that
may be available for histologic examination after 2 to 3 months in
vivo: 1 from the patient with hypoplastic left heart syndrome who
died and 1 from the patient who had to have the tissue-engineered
baffle replaced after 2 months.
Dr Shin’oka, do you have any histologic or immunohistochem-
ical data on either of these scaffolds, or on any other specimens
explanted after a period in vivo? Do you have any preliminary
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Dideas about what happens to the cells that were implanted within
the scaffold?
Dr Shin’oka. First, Dr Mayer, let me express my deep appreci-
ation for your kind instruction when I began the laboratory experi-
ments for tissue engineering in Boston. As you mentioned, many
questions remain to be answered in this field, and as a result I have
been told by others that a clinical application to my research was
premature. However, I have always remembered that you and Dr
Vacanti encouraged me by saying “you have to walk before running.”
Therefore, on the basis of the results of 6 years of research, we have
begun clinical application of vascular grafts in a low-pressure system,
which we assume is the safest region. However, I agree that our
results are just the beginning of a long, long path for successful tissue
engineering in the cardiovascular system.
With regard to your first question concerning histologic
study of explanted specimens from the patient who died and the
patient who underwent reoperation, you are correct in stating
that these specimens provided opportunities for histologic ex-
amination. Unfortunately, the first patient’s family refused an
autopsy. In the case of the patient who underwent reoperation,
we obtained a specimen during that reoperation, 2 months after
implantation (Figure 2).
This specimen demonstrates the partially endothelialized
tissue, which contains the collagen fiber in the medial layer.
However, this tissue was broken by catheterization and is very
fragile in the center of the patch, which shows poor tissue
growth. When the scaffold degraded, the current tissue forma-
tion was insufficient to provide mechanical support. This is a
different situation from that observed in the blood vessels.
Because the outer surface of tissue-engineered vascular grafts
would be covered with the adhesive tissue, this tissue would
reinforce the mechanical properties of the vascular grafts. Be-
cause of these results, we stopped using the PGA scaffold as a
septum in the bloodstream.
Regarding the fate of the seeded cells, as I have shown in this
presentation, we confirmed that many of the seeded BMCs con-
tributed to tissue formation.
Dr Mayer. A second fundamental question is whether it is
even necessary to seed these biodegradable polymer constructs
before implantation, or whether circulating progenitor cells of
bone marrow or other origin could in fact seed a polymer
scaffold in vivo after the naked scaffold was implanted. Do you
have any experience with implantation of the scaffold without
previous seeding with cells? If not, could you speculate on the
potential role of circulating progenitor cells for tissue-engi-
neered structures?
Dr Shin’oka. With regard to the second question concerning
the contribution of circulating progenitor cells, we did implant
many control grafts in the inferior vena cava position without cell
seeding. In 20% of these grafts, good quality vessels developed.
However, the graft occlusion rate was high. When we administered
granulocyte colony-stimulating factor after control graft implanta-
tion, the success rate increased to 50%. Further, when we used the
cell seeding before implantation, the success rate reached approx-
imately 100%.
Because of these results, we continue to use the cell seeding
method before implantation in a clinical setting. The experimental
study showed that the seeded cells produced some cytokines, such
The Journal of Thoracicas vascular endothelial growth factor and angiopoietin 1. We
suggest that these cytokines assist in inducing progenitor cell
migration from the bloodstream. We speculate and provide evi-
dence that the healing mechanism is due to the cooperation be-
tween seeded cells and migrated progenitor cells.
Dr Mayer. And the last fundamental question for cardiovas-
cular tissue engineering is whether the implanted cells on these
conduits will continue to proliferate, causing vascular obstruction,
or in some way or another will “know” when to stop proliferating.
In your series, 2 of the 19 patients receiving tissue-engineered
pulmonary artery patches and 1 patient with a Fontan circulation
required subsequent balloon angioplasty, and in the article you have
attributed these stenoses to presumed tissue overgrowth. What strat-
egies should we use to prevent such tissue overgrowth, and what role
do you think that there might be for the simultaneous seeding of
endothelial cells in addition to BMCs in preventing tissue over-
growth?
Dr Shin’oka. In response to the third question, asking when and
how seeded cells stop proliferating, as you might have noticed in the
clinical setting, the wound healing process is a mysterious function of
the human body. When a skin injury is completely healed, the cells
stop proliferating. The same mechanics may occur in the tissue-
engineering process. Actually, no patients in our series have had
neoplasm formation in our 4-year clinical experience.
The reason for the recurrent pulmonary restenosis is related to
tissue overgrowth that occurred at the anastomosis site, where the
suture material remained. We have no solution for tissue over-
growth at the anastomosis site. In addition, I would like to state
that the wound healing process is different from patient to patient,
an individual process. Most likely, the process that occurs in the
tissue-engineered grafts is similar to this kind of wound healing.
Thank you again for your kind questions.
Dr Thorsten Walles (Hannover, Germany). Reading your ab-
stract, I have one question. I am surprised by the need for anticoagu-
lants for a period of 6 months in your patients, because a functional
tissue-engineered vascular graft should have a functional athrombo-
genic endothelial lining. Did you use any methods before or after
implantation to control endothelial function in your grafts?
Dr Shin’oka. According to the results of the experimental
animal model, endothelialization is complete within 2 weeks;
anticoagulation treatment for 6 months thus may not be required.
In the clinical setting, we desire the best results, but maybe we can
shorten the duration of anticoagulation therapy.
Dr Tirone David (Toronto, Ontario, Canada). No, the ques-
tion is regarding the need for anticoagulation. Why did you anti-
coagulate the patients for 6 months?
Dr Shin’oka. In the experimental animal, endothelialization
was complete within 2 weeks. So maybe we don’t have to use
anticoagulation for 6 months. But in the clinical setting, we want
to have better results. So maybe we can shorten the duration of
anticoagulation therapy.
Dr Walles. But you don’t know if you have endothelial func-
tion and an athrombogenic graft at the time of implantation?
Dr Shin’oka. As you pointed out, tissue-engineered grafts do
not have the functional endothelial cells at the time of implanta-
tion. We therefore used the heparin infusion in acute phase and
used anticoagulation therapy in the middle term. Actually, the
tissue-engineered graft had obtained functioning endothelial cells
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Dwithin 2 weeks, which was confirmed by nitric oxide production,
in an animal model.
Dr Adrian A. Crucean (London, UK). We are currently con-
ducting a similar experiment in Italy. I would like to ask you
whether before using these conduits in human beings you have
done any animal model or in vitro model regarding the potential of
growth for these grafts (designed to be used in the pediatric age
group). What is the smallest graft that you used?
1338 The Journal of Thoracic and Cardiovascular Surgery ● JunDr Shin’oka. The growth potential was confirmed in the grow-
ing animal model. The smallest graft size that we have used in the
clinical setting is now 12 mm.
Dr Smruti R. Mohanty (Bangalore/Karnataka, India). Can
you use BMCs from the sternum?
Dr Shin’oka. We usually aspirate bone marrow from the
anterior iliac spine. The sternum is not suitable to obtain a suffi-
cient number of BMCs.
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TABLE E1. Characteristics of patients (female/male ratio 24:18)
Patient
Age
(y)
Body
weight
(kg) Chief diagnosis
Previous operations Operative
procedure with
tissue-engineered
materials
Scaffold
diameter
(mm)
Components of
biodegradable
scaffold
Radical
operations Palliative operations
Tissue-engineered vascular autografts
1 2 11 Asplenia, AVSD(A), small
RV
mBTS (2) TCPC 16 P(LA/CL)  PLLA
2 1 7.5 Asplenia, SRV, DORV,
TAPVC (Ib)
mBTS TCPC, TAPVC
repair
20 P(LA/CL)  PLLA
3 7 18.5 Concordant criss-cross
heart, DORV, PAA, MS
oBTS, CS, PA
plasty
TCPC 18 P(LA/CL)  PLLA
4 21 44.4 TA (Ib) oBTS (2), CS TCPC 24 P(LA/CL)  PLLA
5 4 14 SRV, DORV, AVVA PAB, PDA ligation,
mBTS, BDG
TCPC 20 P(LA/CL)  PLLA
6 12 36.7 Total sinus defect, ASD,
tricuspid valve
regurgitation (III)
Septation, TVP
(2)
oBTS, PAB TCPC 24 P(LA/CL)  PLLA
7 17 46.5 Asplenia, SLV, CAVVR (III) oBTS, BDG 
CAVVP
TCPC 24 P(LA/CL)  PLLA
8 19 47 TA (Ib) Björk  PDA
ligation
TCPC 22 P(LA/CL)  PLLA
9 3 13.5 Polysplenia, SRV BDG Hepatic vein
rerouting
12 P(LA/CL)  PLLA
10 2 7.5 HLHS, MA, IAA (A) Norwood, mBTS,
BDG
TCPC 16 P(LA/CL)  PLLA
11 2 11 Asplenia, SRV, PAA,
nonconfluent PA
mBTS (2) TCPC 16 P(LA/CL)  PGA
12 13 23 PPA, ASD (II), sinusoidal
communication
oBTS, mBTS TCPC 20 P(LA/CL)  PLLA
13 14 9.9 SLV, DILV, left AVVA TCPC 16 P(LA/CL)  PGA
14 2 9.32 DORV, small LV,
perimembranous VSD,
PS, ASD (II)
mBTS, PAB TCPC 18 P(LA/CL)  PGA
15 2 11 Polysplenia, cAVSD (A),
DORV, PS, CAVVR
Hepatic vein
rerouting
12 P(LA/CL)  PGA
16 2 8.67 Asplenia, SRV, CAVV, CA,
TAPVC (Ib), CAVVR (I)
TAPVC repair BDG TCPC 16 P(LA/CL)  PGA
17 24 51.6 TA (Ia), RA giant
thrombosis, AFL, af,
congestive liver
Fontan (APC) TCPC 18 P(LA/CL)  PGA
18 1 8.7 SRV, DIRV, PA, ASD (II) mBTS TCPC 16 P(LA/CL)  PGA
19 11 25.5 Asplenia, SRV, PS
(inferior and valvular),
CA, CAVV
TCPC 18 P(LA/CL)  PGA
20 2 11 Polysplenia, cAVSD, PS,
CAVV, CAVVR (I)
TCPS Hepatic vein
rerouting
12 P(LA/CL)  PGA
21 3 10.5 DORV, VSD, small RA,
PLSVC, TAPVC (IIb)
TCPC, PVO
release
16 P(LA/CL)  PGA
22 4 13 PPA, ASD (II), PDA,
sinusoidal
communication
mBTS (2) TCPC 18 P(LA/CL)  PGA
23 4 14.2 SLV, DILV, PA, ASD,
bilateral SVC
mBTS (2), BDG TCPC 18 P(LA/CL)  PGA1338.e30 The Journal of Thoracic and Cardiovascular Surgery ● June 2005
TABLE E1. Continued
Patient
Age
(y)
Body
weight
(kg) Chief diagnosis
Previous operations Operative
procedure with
tissue-engineered
materials
Scaffold
diameter
(mm)
Components of
biodegradable
scaffold
Radical
operations Palliative operations
Tissue-engineered sheets
24 6 16.5 TF, PAPVD, valvular
PS
ICR RVOTR P(LA/CL)  PLLA
25 10 36 D-TGA (I), RV outflow
obstruction, branch PS
ASO, PA
plasty
PAP P(LA/CL)  PLLA
26 24 44 TF, PA, conduit stenosis Rastelli Waterston RVOTR P(LA/CL)  PLLA
27 9 29 SRV, DIRV, DORV, branch
PS
Fontan mBTS PAP P(LA/CL)  PLLA
28 7 16.1 TF, branch PS ICR mBTS PAP P(LA/CL)  PLLA
29 1 13.5 IAA (A), branch and main
PA stenosis, SVC
occlusion
ICR, arch
repair
PAP and SVC
Patch
P(LA/CL)  PLLA
30 3 13.8 Polysplenia, SRV, DORV mBTS TCPC (LT) P(LA/CL)  PLLA
31 3 14 Truncus arteriosus
communicans (I),
conduit stenosis
Rastelli (2) PAP P(LA/CL)  PLLA
32 11 36.5 Congenital aortic
regurgitation (III)
RVOTR, Ross P(LA/CL)  PLLA
33 2 8.5 Asplenia, SRV, DORV TCPC (LT) P(LA/CL)  PLLA
34 8 19 DORV, VSD, nonconfluent
PA
mBTS (2), CS 
PAP
PAP P(LA/CL)  PLLA
35 5 14.5 TF, branch PS ICR oBTS, mBTS,
palliative RVOTR
RVOTR P(LA/CL)  PGA
36 7 19.5 Polysplenia, L-DORV, PAA,
bilateral branch PS
Double-switch
operation
mBTS PAP P(LA/CL)  PGA
37 10 17.2 Polysplenia, SRV, left
AVVA, right AVVR (II)
BDG TCPC (LT) P(LA/CL)  PGA
38 17 64 D-TGA (I), supravalvular
PS, AR (II)
ASO RVOTR P(LA/CL)  PGA
39 3 13.8 TAC (II), conduit stenosis,
PAPVR
Rastelli RVOTR P(LA/CL)  PLLA
40 9 42.5 BWG, PS Takeuchi, right
PA
angioplasty
PAP P(LA/CL)  PGA
41 8 20.5 TGA (II), CoA, LMT
occlusion, left PA
stenosis
ASO PAP P(LA/CL)  PGA
42 6 19.5 D-TGA (I), SVAS, left PA
stenosis
ASO PAP P(LA/CL)  PGA
AVSD, Atrioventricular septal defect; RV, right ventricle; mBTS, modified Blalock-Taussig shunt; P(LA/CL), copolymer of L-lactide and -caprolactone;
SRV, single right ventricle; DORV, double-outlet right ventricle; TAPVC, total anomalous pulmonary venous connection; PAA, pulmonary artery
atresia; MS, mitral stenosis; oBTS, original Blalock-Taussig shunt; CS, central shunt; PA, pulmonary artery; TA, tricuspid atresia; AVVA,
atrioventricular valve atresia; PAB, pulmonary arterial banding; PDA, patent ductus arteriosus; BDG, bidirectional Glenn shunt; ASD, atrial septal
defect; TVP, tricuspid valve plasty; SLV, single left ventricle; CAVVR, common atrioventricular valve regurgitation; CAVVP, common atrioventricular
valve plasty; HLHS, hypoplastic left heart syndrome; MA, mitral atresia; IAA, interruption of aortic arch; PPA, pure pulmonary atresia; DILV,
double-inlet left ventricle; LV, left ventricle; VSD, ventricular septal defect; PS, pulmonary stenosis; cAVSD, complete atrioventricular septal defect;
CAVV, common atrioventricular valve; CA, common atrium; RA, right atrium; AFL, atrial flutter; af, atrial fibrillation; APC, atrial premature contraction;
DIRV, double-inlet right ventricle; PLSVC, persistent left superior vena cava; SVC, superior vena cava; TF, tetralogy of Fallot; PAPVD, partial
anomalous pulmonary vein drainage; ICR, intracardiac rerouting; RVOTR, right ventricular outflow tract reconstruction; D-TGA, dextrotransposition
of the great arteries; ASO, arterial switch operation; PAP, pulmonary arterial patch angioplasty; LT, lateral tunnel method; AVVR, atrioventricular
valve regurgitation; AR, aortic regurgitation; TAC, truncus arteriosus; PAPVR, partial anomalous pulmonary vein return; BWG, Bland-White-Garland
syndrome; CoA, coarctation; LMT, left main trunk of coronary artery; SVAS, supravalvular aortic stenosis.
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Figure E1. Scanning electromicroscopic findings of seeded BMCs on polymer scaffold. Bar represents 50 m.
Figure E2. Histologic findings of seeded polymer. A, Mononuclear cells in scaffold (May-Grünwald-Giemsa
staining). B, Immunohistochemical staining for CD34 showed positive cells in scaffold (arrows).1338.e32 The Journal of Thoracic and Cardiovascular Surgery ● June 2005
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Figure E3. Postoperative maximum values of C-reactive protein (max CRP) and white blood cell count (max WBC)
showed no significant difference between groups. TE, Group implanted with tissue-engineered graft.
Figure E4. Three-dimensional computed tomographic image 12 months after implantation of TCPC graft (patient 20).
Red arrow indicates location of tissue-engineered conduit.The Journal of Thoracic and Cardiovascular Surgery ● Volume 129, Number 6 1338.e33
